- Home
- CMBM vs THAR Comparison
CMBM vs THAR Comparison
Compare CMBM & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBM
- THAR
- Stock Information
- Founded
- CMBM 2011
- THAR 2017
- Country
- CMBM United States
- THAR United States
- Employees
- CMBM N/A
- THAR N/A
- Industry
- CMBM Radio And Television Broadcasting And Communications Equipment
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- CMBM Technology
- THAR Health Care
- Exchange
- CMBM Nasdaq
- THAR Nasdaq
- Market Cap
- CMBM 18.6M
- THAR 16.8M
- IPO Year
- CMBM 2019
- THAR 2022
- Fundamental
- Price
- CMBM $0.76
- THAR $2.88
- Analyst Decision
- CMBM Buy
- THAR Strong Buy
- Analyst Count
- CMBM 1
- THAR 1
- Target Price
- CMBM $3.00
- THAR $17.00
- AVG Volume (30 Days)
- CMBM 176.1K
- THAR 29.4M
- Earning Date
- CMBM 11-06-2025
- THAR 11-06-2025
- Dividend Yield
- CMBM N/A
- THAR N/A
- EPS Growth
- CMBM N/A
- THAR N/A
- EPS
- CMBM N/A
- THAR N/A
- Revenue
- CMBM $172,215,000.00
- THAR N/A
- Revenue This Year
- CMBM N/A
- THAR N/A
- Revenue Next Year
- CMBM $17.73
- THAR N/A
- P/E Ratio
- CMBM N/A
- THAR N/A
- Revenue Growth
- CMBM N/A
- THAR N/A
- 52 Week Low
- CMBM $0.23
- THAR $0.95
- 52 Week High
- CMBM $2.08
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- CMBM 52.24
- THAR 46.11
- Support Level
- CMBM N/A
- THAR $2.75
- Resistance Level
- CMBM $0.77
- THAR $3.46
- Average True Range (ATR)
- CMBM 0.05
- THAR 0.81
- MACD
- CMBM -0.02
- THAR -0.30
- Stochastic Oscillator
- CMBM 90.87
- THAR 2.89
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.